A team of researchers at Michigan state University has achieved a breakthrough in cardiac research,developing the first human heart organoid capable of accurately replicating atrial fibrillation,a common and often debilitating heart rhythm disorder affecting an estimated 60 million people globally[[3]]. This innovation offers a perhaps transformative tool for studying the disease-wich has seen limited therapeutic advancements in the past three decades-and for testing new treatments in a more physiologically relevant setting than traditional animal models. The findings, recently published in *cell Stem Cell*, demonstrate the critical role of inflammation in the growth of A-fib and pave the way for more targeted therapies[[1]].
A team of researchers has developed a groundbreaking new model for studying atrial fibrillation, a common heart rhythm disorder affecting millions worldwide. The advance, stemming from work at Michigan State University, could revitalize the search for new treatments, which have largely stalled for over three decades.
Atrial fibrillation causes irregular and often rapid heartbeats, increasing the risk of stroke, heart failure, and other complications. Currently, treatments focus on managing symptoms rather than addressing the underlying causes of the condition. The lack of accurate models to study the disease has been a major hurdle in developing new therapies.
Researchers at Michigan State University have created human heart organoids – tiny, 3D structures grown from human stem cells – that accurately mimic atrial fibrillation. These organoids, about the size of a poppy seed, beat rhythmically and visibly with the naked eye. The development, detailed in a recent study, offers a more realistic way to study the disease and test potential treatments than existing animal models.
The research, which began five years ago, involved using human stem cells capable of transforming into various cell types to build the organoids. These structures contain chambers resembling those of the human heart and a complete network of blood vessels, including arteries, veins, and capillaries. A key breakthrough came with the integration of immune cells, called macrophages, into the organoids.
“In a developing heart, these immune cells are essential for proper growth and organization of the heart tissue,” researchers explained. By inducing inflammation within the organoids, the team successfully triggered irregular heartbeats similar to those seen in atrial fibrillation.
The findings, published in the journal Cell Stem Cell, demonstrate that adding inflammatory molecules caused the irregular heartbeats. Subsequent introduction of an anti-inflammatory drug led to a partial normalization of the heart rhythm. This suggests inflammation plays a critical role in the development of atrial fibrillation.
This new model allows for the direct study of living human heart tissue, something previously unavailable to researchers. The ability to observe the disease process in a human context is expected to accelerate the discovery of more effective treatments.
The study also revealed that innate immune cells, which are long-lasting residents of organs, contribute to the regulation of heart development and rhythm. These observations may also provide insights into the origins of congenital heart defects, the most common birth defects.
Researchers were also able to “age” the organoids by exposing them to inflammation associated with atrial fibrillation, making them more representative of adult hearts. This allows for the study of age-related changes in the disease.
Credit: Michigan State University, December 2025
The technology developed at Michigan State University aligns with initiatives from the National Institutes of Health (NIH) to modernize preclinical research and improve the predictability of testing before clinical trials. Researchers are already collaborating with industry partners to evaluate compounds that could prevent arrhythmias without harming heart health.
Looking ahead, the team plans to develop personalized heart models derived from patient cells, potentially paving the way for precision medicine approaches. They also envision generating heart tissue suitable for transplantation in the future.
“Including components of the immune system makes these models more closely resemble human physiology than any previous version,” the study authors stated. The lack of precise human models has historically limited the discovery of new arrhythmia therapies, and this type of organoid could accelerate research and drug testing, including collaborations with the pharmaceutical and biotechnology industries, to identify effective and safe treatments.
Researchers from Michigan State University, Corewell Health, and Washington University contributed to the study.
